Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;22(9):1293-1302.
doi: 10.1016/S1473-3099(22)00320-6. Epub 2022 Jun 23.

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J Watson  1 , Gregory Barnsley  2 , Jaspreet Toor  2 , Alexandra B Hogan  2 , Peter Winskill  2 , Azra C Ghani  2
Affiliations

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J Watson et al. Lancet Infect Dis. 2022 Sep.

Erratum in

Abstract

Background: The first COVID-19 vaccine outside a clinical trial setting was administered on Dec 8, 2020. To ensure global vaccine equity, vaccine targets were set by the COVID-19 Vaccines Global Access (COVAX) Facility and WHO. However, due to vaccine shortfalls, these targets were not achieved by the end of 2021. We aimed to quantify the global impact of the first year of COVID-19 vaccination programmes.

Methods: A mathematical model of COVID-19 transmission and vaccination was separately fit to reported COVID-19 mortality and all-cause excess mortality in 185 countries and territories. The impact of COVID-19 vaccination programmes was determined by estimating the additional lives lost if no vaccines had been distributed. We also estimated the additional deaths that would have been averted had the vaccination coverage targets of 20% set by COVAX and 40% set by WHO been achieved by the end of 2021.

Findings: Based on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7-15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19·1-20·4) deaths from COVID-19 averted when we used excess deaths as an estimate of the true extent of the pandemic, representing a global reduction of 63% in total deaths (19·8 million of 31·4 million) during the first year of COVID-19 vaccination. In COVAX Advance Market Commitment countries, we estimated that 41% of excess mortality (7·4 million [95% Crl 6·8-7·7] of 17·9 million deaths) was averted. In low-income countries, we estimated that an additional 45% (95% CrI 42-49) of deaths could have been averted had the 20% vaccination coverage target set by COVAX been met by each country, and that an additional 111% (105-118) of deaths could have been averted had the 40% target set by WHO been met by each country by the end of 2021.

Interpretation: COVID-19 vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact in these settings, reinforcing the need for global vaccine equity and coverage.

Funding: Schmidt Science Fellowship in partnership with the Rhodes Trust; WHO; UK Medical Research Council; Gavi, the Vaccine Alliance; Bill & Melinda Gates Foundation; National Institute for Health Research; and Community Jameel.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ACG has received personal consultancy fees from HSBC, GlaxoSmithKline, and WHO related to COVID-19 epidemiology and from The Global Fund to Fight AIDS, Tuberculosis and Malaria for work unrelated to COVID-19. ACG is a non-remunerated member of scientific advisory boards for Moderna and the Coalition for Epidemic Preparedness. ABH and PW have received personal consultancy related to COVID-19 work from WHO. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Global COVID-19 deaths averted due to vaccination based on excess mortality (A) Median number of daily COVID-19 deaths based on excess mortality estimates (grey vertical bars) in the first year of vaccination. The baseline estimate of daily COVID-19 deaths from the model fit to excess mortality is plotted with the solid black line and the counterfactual scenario without vaccines is plotted with a red line. The gap between the red and black line indicates the deaths averted due to vaccination, with the proportion of total deaths averted by direct protection conferred by vaccination shown in blue and indirect protection shown in green. (B) Median number of daily deaths averted per day as per 2022 World Bank income group.
Figure 2
Figure 2
Median deaths averted by vaccinations per 10 000 people by country in the first year of COVID-19 vaccination Estimates of deaths averted were based on model fits to excess mortality and were binned within seven equal quantiles starting at 0 deaths averted. Deaths averted listed as not applicable for China because of its exclusion from our analysis, due to its unique position as the origin of the detected epidemic and large influence on estimates of deaths averted stemming from its population size.
Figure 3
Figure 3
Median deaths averted by vaccinations per 10 000 against vaccinations per 10 000 for each country All measures are on the log-scale. Spearman's rank correlation coefficient (Spearman's ρ) is also given for each income group with a p value based on the Z score against a null hypothesis of no correlation. Countries that did not deliver any vaccinations or had no deaths averted are not included.
See this image and copyright information in PMC

Comment in

Similar articles

  • Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
    Hartner AM, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers MJ, Ferrari MJ, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore SM, Nayagam S, Papadopoulos T, Perkins TA, Portnoy A, Minh QT, Vynnycky E, Winter AK, Burrows H, Chen C, Clapham HE, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim JH, Koh J, Lopman BA, Pitzer VE, Tam Y, Lambach P, Sim SY, Woodruff K, Ferguson NM, Trotter CL, Gaythorpe KAM. Hartner AM, et al. Lancet Glob Health. 2024 Apr;12(4):e563-e571. doi: 10.1016/S2214-109X(23)00603-4. Lancet Glob Health. 2024. PMID: 38485425 Free PMC article.
  • Inequities in the deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region, 2020-2021.
    Hasan Q, Elfakki E, Fahmy K, Mere O, Ghoniem A, Langar H, Musa N, Attia R, Othman MM, Samhouri D, Chaudhri I, Abubakar A, Hajjeh R, Hutin YJ. Hasan Q, et al. BMJ Glob Health. 2022 Jun;7(Suppl 4):e008139. doi: 10.1136/bmjgh-2021-008139. BMJ Glob Health. 2022. PMID: 35764354 Free PMC article. Review.
  • Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.
    Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, Clark A, de Villiers MJ, Eilertson K, Ferrari M, Gamkrelidze I, Hallett TB, Hinsley WR, Hogan D, Huber JH, Jackson ML, Jean K, Jit M, Karachaliou A, Klepac P, Kraay A, Lessler J, Li X, Lopman BA, Mengistu T, Metcalf CJE, Moore SM, Nayagam S, Papadopoulos T, Perkins TA, Portnoy A, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Tam Y, Tanvir H, Tran Minh Q, Trotter CL, Truelove SA, Vynnycky E, Walker N, Winter A, Woodruff K, Ferguson NM, Gaythorpe KA. Toor J, et al. Elife. 2021 Jul 13;10:e67635. doi: 10.7554/eLife.67635. Elife. 2021. PMID: 34253291 Free PMC article.
  • Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze I, Gaythorpe KAM, Grassly NC, Hallett TB, Hinsley W, Jackson ML, Jean K, Karachaliou A, Klepac P, Lessler J, Li X, Moore SM, Nayagam S, Nguyen DM, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Sy S, Tam Y, Tanvir H, Tran QM, Trotter CL, Truelove S, van Zandvoort K, Verguet S, Walker N, Winter A, Woodruff K, Ferguson NM, Garske T; Vaccine Impact Modelling Consortium. Li X, et al. Lancet. 2021 Jan 30;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X. Lancet. 2021. PMID: 33516338 Free PMC article.
  • The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance.
    Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, Reef SE, Schwalbe N, Simons E, Strebel PM, Sweet S, Suraratdecha C, Tam Y, Vynnycky E, Walker N, Walker DG, Hansen PM. Lee LA, et al. Vaccine. 2013 Apr 18;31 Suppl 2:B61-72. doi: 10.1016/j.vaccine.2012.11.035. Vaccine. 2013. PMID: 23598494 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. NHS Landmark moment as first NHS patient receives COVID-19 vaccination. Dec 8, 2020. https://www.england.nhs.uk/2020/12/landmark-moment-as-first-nhs-patient-...
    1. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data. 2020. https://ourworldindata.org/coronavirus
    1. Imai N, Hogan AB, Williams L, et al. Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. Wellcome Open Res. 2021;6:185.
    1. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397:1023–1034. - PMC - PubMed
    1. WHO Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility. Sept 9, 2020. https://www.who.int/publications/m/item/fair-allocation-mechanism-for-co...

Publication types

-